What are the problems with Fasenra? A Comprehensive Overview
•
3 min read
While Fasenra (benralizumab) is an effective add-on maintenance treatment for severe eosinophilic asthma and EGPA, it is not without its challenges. A significant reported issue is its high cost, with some patients citing a major financial burden despite effective symptom control. Furthermore, like all medications, it carries a risk of side effects, ranging from common, mild reactions to rare, serious allergic responses.
